Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00346827
Recruitment Status : Unknown
Verified June 2006 by Britannia Pharmaceuticals Ltd..
Recruitment status was:  Not yet recruiting
First Posted : June 30, 2006
Last Update Posted : June 30, 2006
Information provided by:
Britannia Pharmaceuticals Ltd.

Brief Summary:
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: Apomorphine Nasal Powder Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day

Exclusion Criteria:

  • hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00346827

Sponsors and Collaborators
Britannia Pharmaceuticals Ltd.
Principal Investigator: Richard Weiser, MB, MRCP Swansea Hospital, Swansea, Wales Identifier: NCT00346827     History of Changes
Other Study ID Numbers: 20102D05
First Posted: June 30, 2006    Key Record Dates
Last Update Posted: June 30, 2006
Last Verified: June 2006

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action